288 related articles for article (PubMed ID: 25325179)
1. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluation.
Evans M; McEwan P; Foos V
J Med Econ; 2015 Feb; 18(2):96-105. PubMed ID: 25325179
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of switching to insulin degludec from other basal insulins in real-world clinical practice in Italy.
Haldrup S; Lapolla A; Gundgaard J; Wolden ML
J Med Econ; 2020 Mar; 23(3):271-279. PubMed ID: 31526202
[No Abstract] [Full Text] [Related]
3. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
Jendle J; Ericsson Å; Ekman B; Sjöberg S; Gundgaard J; da Rocha Fernandes J; Mårdby AC; Hunt B; Malkin SJP; Thunander M
J Med Econ; 2020 Nov; 23(11):1311-1320. PubMed ID: 32746676
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
J Med Econ; 2015 Jan; 18(1):56-68. PubMed ID: 25271378
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
Ericsson Å; Pollock RF; Hunt B; Valentine WJ
J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
[TBL] [Abstract][Full Text] [Related]
7. Switching "Real-World" Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control.
Tentolouris N; Knudsen ST; Lapolla A; Wolden ML; Haldrup S; Schultes B
Adv Ther; 2019 May; 36(5):1201-1210. PubMed ID: 30879256
[TBL] [Abstract][Full Text] [Related]
8. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.
Rodbard HW; Gough S; Lane W; Korsholm L; Bretler DM; Handelsman Y
Endocr Pract; 2014 Apr; 20(4):285-92. PubMed ID: 24246344
[TBL] [Abstract][Full Text] [Related]
9. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
[TBL] [Abstract][Full Text] [Related]
10. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.
Landstedt-Hallin L; Gundgaard J; Ericsson Å; Ellfors-Zetterlund S
Curr Med Res Opin; 2017 Apr; 33(4):647-655. PubMed ID: 28035840
[TBL] [Abstract][Full Text] [Related]
12. Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK.
Thalange N; Gundgaard J; Parekh W; Tutkunkardas D
BMJ Open Diabetes Res Care; 2019; 7(1):e000664. PubMed ID: 31543973
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Dehghani M; Sadeghi M; Barzkar F; Maghsoomi Z; Janani L; Motevalian SA; Loke YK; Ismail-Beigi F; Baradaran HR; Khamseh ME
Front Endocrinol (Lausanne); 2024; 15():1286827. PubMed ID: 38586456
[TBL] [Abstract][Full Text] [Related]
14. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
Pollock RF; Tikkanen CK
J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
[TBL] [Abstract][Full Text] [Related]
15. Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine.
Weatherall J; Bloudek L; Buchs S
Curr Med Res Opin; 2017 Feb; 33(2):231-238. PubMed ID: 27764979
[TBL] [Abstract][Full Text] [Related]
16. Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.
Fadini GP; Feher M; Hansen TK; de Valk HW; Koefoed MM; Wolden M; Zimmermann E; Jendle J
J Clin Endocrinol Metab; 2019 Dec; 104(12):5977-5990. PubMed ID: 31397845
[TBL] [Abstract][Full Text] [Related]
17. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial.
Davies M; Sasaki T; Gross JL; Bantwal G; Ono Y; Nishida T; Tojjar D; Seino H
Diabetes Obes Metab; 2016 Jan; 18(1):96-9. PubMed ID: 26435472
[TBL] [Abstract][Full Text] [Related]
18. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables.
Lane WS; Weatherall J; Gundgaard J; Pollock RF
J Med Econ; 2018 Feb; 21(2):144-151. PubMed ID: 28945173
[TBL] [Abstract][Full Text] [Related]
19. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
[TBL] [Abstract][Full Text] [Related]
20. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
